Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Tolmeijer SH, van Wilpe S, Geerlings MJ, von Rhein D, Smilde TJ, Kloots ISH, Westdorp H, Coskuntürk M, Oving IM, van Ipenburg JA, van der Heijden AG, Hofste T, Weiss MM, Schalken JA, Gerritsen WR, Ligtenberg MJL, Mehra N. Tolmeijer SH, et al. Among authors: schalken ja. Eur Urol Oncol. 2024 Apr;7(2):282-291. doi: 10.1016/j.euo.2023.08.009. Epub 2023 Sep 4. Eur Urol Oncol. 2024. PMID: 37673768 Free article.
Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial.
Weijers JAM, de Bitter TJJ, Verhaegh GW, van Boxtel W, Uijen MJM, van Engen-van Grunsven ACH, Driessen CML, Schalken JA, Ligtenberg MJL, van Herpen CML. Weijers JAM, et al. Among authors: schalken ja. Oral Oncol. 2023 Dec;147:106620. doi: 10.1016/j.oraloncology.2023.106620. Epub 2023 Nov 6. Oral Oncol. 2023. PMID: 37939426 No abstract available.
Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.
Lassche G, van Engen-van Grunsven ACH, van Hooij O, Aalders TW, Am Weijers J, Cocco E, Drilon A, Hoischen A, Neveling K, Schalken JA, Verhaegh GW, van Herpen CML. Lassche G, et al. Among authors: schalken ja. Oral Oncol. 2023 Feb;137:106297. doi: 10.1016/j.oraloncology.2022.106297. Epub 2023 Jan 5. Oral Oncol. 2023. PMID: 36610231 Free PMC article.
TTLL12 has a potential oncogenic activity, suppression of ligation of nitrotyrosine to the C-terminus of detyrosinated α-tubulin, that can be overcome by molecules identified by screening a compound library.
Deshpande A, Brants J, Wasylyk C, van Hooij O, Verhaegh GW, Maas P, Schalken JA, Wasylyk B. Deshpande A, et al. Among authors: schalken ja. PLoS One. 2024 Feb 23;19(2):e0296960. doi: 10.1371/journal.pone.0296960. eCollection 2024. PLoS One. 2024. PMID: 38394155 Free PMC article.
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.
Weijers JAM, Verhaegh GW, Lassche G, van Engen-van Grunsven ACH, Driessen CML, van Erp NP, Jonker MA, Schalken JA, van Herpen CML. Weijers JAM, et al. Among authors: schalken ja. BMC Cancer. 2024 Sep 20;24(1):1174. doi: 10.1186/s12885-024-12889-0. BMC Cancer. 2024. PMID: 39304797 Free PMC article.
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
Slootbeek PHJ, Luna-Velez MV, Privé BM, van der Doelen MJ, Kloots ISH, Pamidimarri Naga S, Onstenk HE, Nagarajah J, Westdorp H, van Oort IM, Kroeze LI, Schalken JA, Bloemendal HJ, Mehra N. Slootbeek PHJ, et al. Among authors: schalken ja. Theranostics. 2024 Aug 1;14(12):4555-4569. doi: 10.7150/thno.96322. eCollection 2024. Theranostics. 2024. PMID: 39239510 Free PMC article.
371 results